Laboratorios Farmaceuticos Rovi

Company Description

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spanish pharmaceutical company focused on the development and commercialization of medicines and drugs. It operates in Diagnostics (contrast mediums), Prescription (Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi, Absorcol), and Over The Counter (Perspirex, Enerzona, Dentimelo, ColdPack) fields. ROVI operates nationwide and abroad, with subsidiaries including Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL, and Bertex Pharma GmbH. In the last fiscal year, the company had 2179 employees, a market cap of $3215 million, profits of $495 million, and revenue of $791 million.

Analysis

ANALYSIS: With an Obermatt 360° View of 90 (better than 90% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Laboratorios Farmaceuticos Rovi are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Laboratorios Farmaceuticos Rovi. The consolidated Growth Rank has a good rank of 73, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 73% of competitors in the same industry. The consolidated Safety Rank at 86 means that the company has a financing structure that is safer than 86% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 83, which means that professional investors are more optimistic about the stock than for 83% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 23, meaning that the share price of Laboratorios Farmaceuticos Rovi is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 77% of alternative stocks in the same industry. ...read more

Country

Spain

Industry Pharmaceuticals

Size Small

Website rovi.es

Index

Add to Watchlist

See Similar Stocks

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.